Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer
Frontiers in Oncology · 18.06.2026 · 16
DOI: 10.3389/fonc.2026.1824808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 18.06.2026. Verfasst von Yi Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Meizhou People's Hospital, Meizhou, China. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer (BC) determines the options for targeted therapy. Multiparametric MRI (mpMRI) has the potential for noninvasive HER2 status prediction but remains underexplored.
Objectives
To develop and validate an mpMRI-based nomogram incorporating clinicopathological factors for predicting HER2 status in BC patients.
Methods
In this retrospective analysis, 313 BC patients were classified as HER2-overexpression, HER2-low, or HER2-zero on the basis of immunohistochemistry and fluorescence in situ hybridization. The patients were divided into training (n=232) and validation (n=81) datasets. Clinicopathological factors and mpMRI parameters were analyzed. Logistic regression identified independent predictors that were used to construct and validate the nomogram. Discrimination was evaluated by the area under the receiver operating characteristic curve (AUC).
Results
CA125, Ki-67, the minimum apparent diffusion coefficient (ADC-min), and early-phase maximum enhancement (ME) differed significantly among the HER2 subgroups. The nomogram integrating these factors achieved AUCs of 0.762 (95% CI: 0.686–0.838) and 0.738 (95% CI: 0.594–0.882) in differentiating HER2-over/HER2-low from HER2-zero in the training and validation datasets, respectively. Differentiation between the HER2-over and HER2-low subtypes exhibited AUCs of 0.719 and 0.772, respectively.
Conclusions
Our nomogram, which combines mpMRI and clinicopathological variables, effectively predicts HER2 expression in BC patients, providing a promising noninvasive clinical tool to guide targeted therapy selection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Meizhou People's Hospital, Meizhou, China.
- Department of Radiology, Affiliated Meizhou Hospital of Shantou University Medical College, Meizhou, China.
- Department of Radiology, Shantou Central Hospital, Shantou, China.
Zitieren
APA
Chen, Y., Chen, X., Yue, B., Zhong, X., Zhang, H., Chen, X., Chen, X., Dai, Z., & Yang, Z. (2026). Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1824808
Vancouver
Chen Y, Chen X, Yue B, Zhong X, Zhang H, Chen X, et al. Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1824808
BibTeX
@article{Chen2026,
author = {Chen, Yi and Chen, Xiaofeng and Yue, Bowen and Zhong, Xinwei and Zhang, Hao and Chen, Xiaohong and Chen, Xiangguang and Dai, Zhuozhi and Yang, Zhiqi},
title = {Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1824808}
}
EUVIMED